An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
Public ClinicalTrials.gov record NCT00332917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
Study identification
- NCT ID
- NCT00332917
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 224 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2007
- Primary completion
- Jun 30, 2008
- Completion
- Jun 30, 2008
- Last update posted
- Jan 25, 2009
2007 – 2008
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 284 | Huntsville | Alabama | — | — |
| Site 274 | Little Rock | Arkansas | — | — |
| Site 283 | Fountain Valley | California | — | — |
| Site 277 | La Jolla | California | — | — |
| Site 271 | San Francisco | California | — | — |
| Site 279 | Fort Lauderdale | Florida | — | — |
| Site 293 | Gainsville | Florida | — | — |
| Site 282 | Port Charlotte | Florida | — | — |
| Site 285 | Sunrise | Florida | — | — |
| Site 273 | Tampa | Florida | — | — |
| Site 290 | Chicago | Illinois | — | — |
| Site 280 | Kansas City | Kansas | — | — |
| Site 292 | Bingham Farms | Michigan | — | — |
| Site 275 | Traverse City | Michigan | — | — |
| Site 276 | St Louis | Missouri | — | — |
| Site 287 | St Louis | Missouri | — | — |
| Site 278 | Las Vegas | Nevada | — | — |
| Site 286 | Rochester | New York | — | — |
| Site 288 | Ashville | North Carolina | — | — |
| Site 289 | Charlotte | North Carolina | — | — |
| Site 294 | Toledo | Ohio | — | — |
| Site 281 | Pittsburgh | Pennsylvania | — | — |
| Site 291 | Warwick | Rhode Island | — | — |
| Site 272 | Houston | Texas | — | — |
| Site 270 | Bennington | Vermont | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00332917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 25, 2009 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00332917 live on ClinicalTrials.gov.